13‐cis‐retinoic acid induces cellular differentiation and durable remission in refractory cutaneous ki‐1 lymphoma

Jyh‐Ming ‐M Chow, Ann‐Lii ‐L Cheng, Ih‐Jen ‐J Su, Chiu‐Hwa ‐H Wang

Research output: Contribution to journalArticlepeer-review

22 Citations (Scopus)

Abstract

A 35‐year‐old man with refractory cutaneous Ki‐1 lymphoma was salvaged successfully with oral 13‐cis‐retinoic acid (1 mg/kg/day). He had a complete remission lasting for 20 months before a single nodule recurred on his skin. Excisional biopsy of the recurrent tumor revealed a distinct morphologic change, suggesting cellular differentiation toward a more benign phenotype. No significant side effects were noted except mild xerostomia, bone pain, and hyperlipidemia. The authors believe that 13‐cis‐retinoic acid should be considered in the treatment of cutaneous Ki‐1 lymphoma.

Original languageEnglish
Pages (from-to)2490-2494
Number of pages5
JournalCancer
Volume67
Issue number10
DOIs
Publication statusPublished - May 15 1991

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of '13‐cis‐retinoic acid induces cellular differentiation and durable remission in refractory cutaneous ki‐1 lymphoma'. Together they form a unique fingerprint.

Cite this